a public good project by the
Synthesis
Company
of California

© 2026

Christine L. Baker | doi.page

0 works0 citations0 h-index

Christine L. Baker

Pfizer (United States)(US)The Fertilizer Institute(US)

Publications by Year

Research Areas

Smoking Behavior and Cessation, Chronic Obstructive Pulmonary Disease (COPD) Research, Atrial Fibrillation Management and Outcomes, Hemoglobinopathies and Related Disorders, Health Systems, Economic Evaluations, Quality of Life

Most-Cited Works

→ Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer(2011)375 cited
→ Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire(2006)242 cited
→ Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt(2007)199 cited
→ Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation Model(2008)98 cited
→ Risk assessment of readmissions following an initial COPD-related hospitalization(2013)95 cited
→ OESTRADIOL-17α AND PITUITARY RESPONSIVENESS TO LUTEINIZING HORMONE RELEASING FACTOR IN THE RAT: A STUDY USING RECTANGULAR PULSES OF OESTRADIOL-17β MONITORED BY NON-CHROMATOGRAPHIC RADIOIMMUNOASSAY(1977)91 cited

→ Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale(2005)

75 cited

→ Benefits of quitting smoking on work productivity and activity impairment in the United States, the European Union and China(2017)65 cited

→ The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO Model(2009)59 cited

→ Real-world characterization and differentiation of the Global Initiative for Chronic Obstructive Lung Disease strategy classification(2014)44 cited